WuXi Vaccines Opens First Vaccines CDMO Site in China


Plant will handle end-to-end services in effort to accelerate project time.

Dedicated scientist group working on advance biotechnology computer software to study or analyze DNA data after making scientific breakthrough from chemical experiment on medical laboratory. Neoteric. Image Credit: Adobe Stock Images/Blue Planet Studio

Image Credit: Adobe Stock Images/Blue Planet Studio

WuXi Vaccines, a contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.

The opening is expected to add drug substance and drug product capacity, with end-to-end services for vaccines that are expected to help speed up timelines—from process development and drug product development to clinical-scale drug substance (DS) and small-to-medium sterile drug product (DP) manufacturing. Its DS production area includes two cell culture lines and one purification line supporting DS production scales from 50L to 1,000L, while maintaining a reserved capacity for 2,000L production.

"We are very pleased with the opening at our first standalone vaccine CDMO site in China,” says Jian Dong, CEO of WuXi Vaccines. “This is a great achievement for our company as it allows us to significantly expand our services and capacities. We look forward to working with our global partners to advance their pipelines, with the ultimate goal of improving the well-being of people worldwide."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.